Marc L. Turner

Heriot Watt Research Park
Edinburgh, SCT, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 64 publications

Autologous macrophage therapy increases transplant-free survival in cirrhosis: Long-term follow-up of a phase 2 clinical trial.

Autologous macrophage therapy increases transplant-free survival in cirrhosis: Long-term follow-up of a phase 2 clinical trial.

Journal: Cell stem cell

Published: December 04, 2025

Toward standardized iPSC testing: Insights from a multi-year international Quality Assessment Round.

Toward standardized iPSC testing: Insights from a multi-year international Quality Assessment Round.

Journal: Stem cell reports

Published: November 27, 2025

Risk of transmission of amyloid β pathology via transfused blood products.

Risk of transmission of amyloid β pathology via transfused blood products.

Journal: Lancet (London, England)

Published: October 25, 2025

ATMPs prepared under hospital exemption: European Blood Alliance position paper.

ATMPs prepared under hospital exemption: European Blood Alliance position paper.

Journal: HemaSphere

Published: August 05, 2025

The infected blood inquiry report-lessons for gamete donation.

The infected blood inquiry report-lessons for gamete donation.

Journal: Human fertility (Cambridge, England)

Published: December 09, 2024

Harnessing global HLA data for enhanced patient matching in iPSC haplobanks.

Harnessing global HLA data for enhanced patient matching in iPSC haplobanks.

Journal: Cytotherapy

Published: September 23, 2024

Cryopreserved human alternatively activated macrophages promote resolution of acetaminophen-induced liver injury in mouse.

Cryopreserved human alternatively activated macrophages promote resolution of acetaminophen-induced liver injury in mouse.

Journal: NPJ Regenerative medicine

Published: June 24, 2024

Autologous macrophage therapy for liver cirrhosis: a phase 2 open-label randomized controlled trial.

Autologous macrophage therapy for liver cirrhosis: a phase 2 open-label randomized controlled trial.

Journal: Nature medicine

Published: June 05, 2024

EBV T-cell immunotherapy generated by peptide selection has enhanced effector functionality compared to LCL stimulation.

EBV T-cell immunotherapy generated by peptide selection has enhanced effector functionality compared to LCL stimulation.

Journal: Frontiers in immunology

Published: April 04, 2024

Subclinical infection occurs frequently following low dose exposure to prions by blood transfusion.

Subclinical infection occurs frequently following low dose exposure to prions by blood transfusion.

Journal: Scientific reports

Published: April 01, 2022

Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses.

Fatal COVID-19 outcomes are associated with an antibody response targeting epitopes shared with endemic coronaviruses.

Journal: JCI insight

Published: November 09, 2021

Study protocol: a multicentre, open-label, parallel-group, phase 2, randomised controlled trial of autologous macrophage therapy for liver cirrhosis (MATCH).

Study protocol: a multicentre, open-label, parallel-group, phase 2, randomised controlled trial of autologous macrophage therapy for liver cirrhosis (MATCH).

Journal: BMJ open

Published: November 09, 2021

Showing 1-12 of 64

Last Updated: 09/26/2026